Jourdeness Group Ltd. AI Stock Analysis
Jourdeness Group Ltd. (4190) AI Stock Analysis
Jourdeness Group Ltd.
(TWSE:4190)
The score is held back primarily by weak fundamentals: three consecutive years of net losses, revenue roughly 22% below its 2023 peak, negative ROE of -5.8%, and a strained balance sheet with debt at 1.72x shrinking equity. Technical signals compound the caution, with the price below all key moving averages and negative MACD, though extremely low RSI and Stochastic readings indicate the stock is heavily oversold. On the positive side, losses narrowed by roughly two-thirds year over year, gross margin improved to 64.1%, and cash generation remains robust - operating cash flow of NT$511m and free cash flow of NT$427m support a 2.24% dividend yield and debt reduction. A negative P/E of -15.7 leaves valuation dependent on cash flow rather than earnings. The investment case rests on whether the loss-narrowing trend can be sustained into genuine profitability and lower leverage.
Jourdeness Group Ltd. (4190) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- TWD 1.30B
- Dividend Yield
- 2.30%
- Average Volume (3M)
- 20.28K
- Price to Earnings (P/E)
- -13.6
- Beta (1Y)
- 0.40
- Revenue Growth
- -1.05%
- EPS Growth
- 34.07%
- Country
- TW
- Employees
- 6,108
- Sector
- General
- Sector Strength
- 55
- Industry
- Household & Personal Products
Jourdeness Group Ltd. Business Overview & Revenue Model
Company Description
Jourdeness Group Limited, together with its subsidiaries, manufactures and sells cosmetics in China, Taiwan, and internationally. The company also engages in the beauty and body spa business; and operation of a tourist factory, as well as offers cons...
Jourdeness Group Ltd. Financial Statement Overview
Summary
Jourdeness remains loss-making for a third straight year, with a net loss of NT$94m (-4.1% net margin) and an operating loss of about NT$86m, though both narrowed sharply (roughly 68-69%) versus 2024. Revenue has stabilized near NT$2.31bn but is still about 22% below the 2023 peak, and gross margin of 64.1%, while improved, trails the 73-76% achieved in 2020-2021. The balance sheet is the weakest link: debt of NT$2.82bn against equity of just NT$1.64bn gives leverage of 1.72x, with equity down nearly 30% since 2021 and ROE still negative at -5.8%. The offsetting strength is cash generation - operating cash flow of NT$511m (up 23%) and free cash flow of NT$427m - which comfortably exceeds the reported loss and funds debt service and capex, confirming the red ink is largely depreciation-driven. Overall, a turnaround in progress but still a higher-risk financial profile.
Income Statement
38NegativeBalance Sheet
36NegativeCash Flow
63Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.26B | 2.31B | 2.28B | 2.98B | 2.78B | 2.82B |
| Gross Profit | 1.32B | 1.48B | 1.40B | 2.01B | 1.89B | 2.06B |
| EBITDA | 417.11M | 615.39M | 535.32M | 878.66M | 802.49M | 1.14B |
| Net Income | -83.95M | -94.26M | -291.95M | -258.00K | 13.98M | 292.16M |
Balance Sheet | ||||||
| Total Assets | 7.25B | 6.79B | 7.39B | 7.86B | 8.05B | 8.44B |
| Cash, Cash Equivalents and Short-Term Investments | 1.77B | 1.16B | 1.15B | 1.33B | 1.37B | 2.44B |
| Total Debt | 3.33B | 2.82B | 3.03B | 3.01B | 3.00B | 3.51B |
| Total Liabilities | 5.63B | 5.16B | 5.62B | 5.78B | 5.89B | 6.16B |
| Stockholders Equity | 1.61B | 1.64B | 1.77B | 2.08B | 2.16B | 2.28B |
Cash Flow | ||||||
| Free Cash Flow | 437.97M | 426.82M | 256.20M | 339.17M | -40.59M | 354.33M |
| Operating Cash Flow | 509.89M | 511.35M | 416.51M | 715.79M | 747.12M | 985.77M |
| Investing Cash Flow | -111.70M | -235.93M | -36.49M | -1.09B | -532.66M | -875.22M |
| Financing Cash Flow | 174.12M | -404.07M | -356.40M | -367.71M | -1.05B | 801.72M |
Jourdeness Group Ltd. Peers Comparison
Overall Rating
TW:316471Outperform
TW:684655Neutral
TW:180544Neutral- TW:419043Neutral
TW:657842Neutral
TW:643138Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| TW:3164 | 71Outperform | TWD 1.44B | 20.68 | ― | 4.78% | 1.32% | 80.16% |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| TW:6846 | 55Neutral | TWD 1.33B | 10.22 | ― | 8.05% | -3.09% | -27.22% |
| TW:1805 | 44Neutral | TWD 1.31B | 71.02 | ― | ― | -59.33% | -94.38% |
| TW:4190 | 43Neutral | TWD 1.29B | -13.57 | ― | 2.30% | -1.05% | 34.07% |
| TW:6578 | 42Neutral | TWD 1.21B | -50.46 | ― | 2.37% | 21.50% | -5.51% |
| TW:6431 | 38Underperform | TWD 1.45B | -7.50 | ― | ― | -14.57% | 13.16% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TW:4190 | Jourdeness Group Ltd. | 21.75 | -9.03 | -29.35% | |
| TW:1805 | Better Life Group Co., Ltd. | 9.68 | -2.02 | -17.26% | |
| TW:3164 | GenMont Biotech, Inc. | 16.75 | -0.96 | -5.41% | |
| TW:6431 | Kuangli Bio-Tech Holdings Co., Ltd. | 14.85 | -1.45 | -8.90% | |
| TW:6578 | Dabomb Protein Biotech Corporation | 16.90 | -2.80 | -14.21% | |
| TW:6846 | Greenyn Biotechnology Co., Ltd. | 49.00 | -24.13 | -32.99% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 09, 2026